Gain Therapeutics receives Australian approval of Phase 1b dosing extension

Gain Therapeutics (GANX) announced the Company has received approval from the Bellberry Human Research Ethics Committee and Alfred Hospital Ethics Committee to extend dosing by an additional nine months in its ongoing Phase 1b clinical study of GT-022887, beyond the 90-day period currently allowed in protocol. The dosing extension will be offered to participants who have completed 90 days of treatment and will provide them the opportunity to continue treatment with GT-02287 for a total of 12 months. The majority of participants who have already completed the 90-day dosing period have confirmed their interest in joining the extension. Separately, the independent data monitoring committee has identified no safety concerns and recommended to continue the study with no changes after its review of interim safety data from the ongoing Phase 1b study of GT-02287.